$0.9799
0.0298[3.14%]
At close: Apr 29
$0.9799
0[0.00%]
PreMarket: 5:43PM EDT
MiNK Therapeutics
(NASDAQ:INKT)MiNK Therapeutics Stock (NASDAQ:INKT), Analyst Ratings, Price Targets, Predictions
MiNK Therapeutics Inc has a consensus price target of $9.6, established from looking at the 11 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on March 21, 2024, August 10, 2023, and May 12, 2023. With an average price target of $9.67 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 886.50% upside for MiNK Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Evercore ISI Group
B. Riley Securities
William Blair
Baird
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for MiNK Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/21/2024 | INKT | Buy Now | MiNK Therapeutics | $0.98 | 818.46% | HC Wainwright & Co. | Emily Bodnar | $10 → $9 | Maintains | Buy | Get Alert |
| 08/10/2023 | INKT | Buy Now | MiNK Therapeutics | $0.98 | 920.51% | HC Wainwright & Co. | Emily Bodnar | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | INKT | Buy Now | MiNK Therapeutics | $0.98 | 920.51% | HC Wainwright & Co. | Emily Bodnar | $7 → $10 | Maintains | Buy | Get Alert |
| 04/19/2023 | INKT | Buy Now | MiNK Therapeutics | $0.98 | 614.36% | HC Wainwright & Co. | Emily Bodnar | → $7 | Reiterates | → Buy | Get Alert |
| 03/22/2023 | INKT | Buy Now | MiNK Therapeutics | $0.98 | 206.15% | Evercore ISI Group | Maneka Mirchandaney | $4 → $3 | Maintains | Outperform | Get Alert |
| 03/22/2023 | INKT | Buy Now | MiNK Therapeutics | $0.98 | 614.36% | HC Wainwright & Co. | Emily Bodnar | → $7 | Reiterates | → Buy | Get Alert |
| 08/10/2022 | INKT | Buy Now | MiNK Therapeutics | $0.98 | 614.36% | HC Wainwright & Co. | Emily Bodnar | → $7 | Initiates | → Buy | Get Alert |
| 01/24/2022 | INKT | Buy Now | MiNK Therapeutics | $0.98 | 920.51% | B. Riley Securities | Kalpit Patel | $24 → $10 | Maintains | Buy | Get Alert |
| 11/09/2021 | INKT | Buy Now | MiNK Therapeutics | $0.98 | — | William Blair | Matt Phipps | — | Initiates | → Outperform | Get Alert |
| 11/09/2021 | INKT | Buy Now | MiNK Therapeutics | $0.98 | 2961.54% | Evercore ISI Group | Maneka Mirchandaney | — | Initiates | → Outperform | Get Alert |
| 11/09/2021 | INKT | Buy Now | MiNK Therapeutics | $0.98 | 2553.33% | Baird | Jack Allen | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for MiNK Therapeutics (INKT)?
The latest price target for MiNK Therapeutics (NASDAQ: INKT) was reported by HC Wainwright & Co. on March 21, 2024. The analyst firm set a price target for $9.00 expecting INKT to rise to within 12 months (a possible 818.46% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for MiNK Therapeutics (INKT)?
The latest analyst rating for MiNK Therapeutics (NASDAQ: INKT) was provided by HC Wainwright & Co., and MiNK Therapeutics maintained their buy rating.
When was the last upgrade for MiNK Therapeutics (INKT)?
There is no last upgrade for MiNK Therapeutics.
When was the last downgrade for MiNK Therapeutics (INKT)?
There is no last downgrade for MiNK Therapeutics.
When is the next analyst rating going to be posted or updated for MiNK Therapeutics (INKT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MiNK Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MiNK Therapeutics was filed on March 21, 2024 so you should expect the next rating to be made available sometime around March 21, 2025.
Is the Analyst Rating MiNK Therapeutics (INKT) correct?
While ratings are subjective and will change, the latest MiNK Therapeutics (INKT) rating was a maintained with a price target of $10.00 to $9.00. The current price MiNK Therapeutics (INKT) is trading at is $0.98, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.